What Does Vyne Therapeutics (VYNE) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
VYNE (VYNE) is a clinical-stage biotech built on a BET inhibitor platform, where the progress of VYN202 clinical trials and cash runway are key stock-price drivers.
Subscribe🏢 What kind of company is Vyne Therapeutics?
VYNE Therapeutics (VYNE) is a clinical-stage biotech headquartered in Bridgewater, New Jersey, USA, focused on selectively inhibiting BET (Bromodomain and Extra-Terminal) proteins to treat immune and inflammatory diseases. Its current CEO is David Domzalski. After winding down its legacy dermatology pharmaceutical business, the company has been reshaped since 2023 as a clinical pipeline company centered on its proprietary InhiBET™ platform.
It has two core candidates: the topically administered pan-BET inhibitor Repibresib (VYN201) and the oral BD2-selective BET inhibitor VYN202, both of which have been advanced in clinical trials across multiple indications, including plaque psoriasis, vitiligo, and myeloproliferative neoplasms.
💰 How does it make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Royalty Revenue | Largest share | Royalties from the Finacea foam previously licensed to LEO Pharma |
| R&D Revenue | Minimal | No commercialized products — business is centered on clinical pipeline development |
| Licensing & Partnerships | Lumpy | One-time revenue expected if co-development or licensing deals are signed for VYN201 or VYN202 |
Because VYNE does not yet have a commercialized proprietary drug, its annual revenue ($0.5M) is extremely small, and most of its costs come from research and development (R&D) spending. General metrics such as profit margin (-4726.2%) and revenue growth (-25.0%) are not very useful for valuing the company; clinical pipeline data, cash balance, and quarterly R&D spending are far more important indicators.
📐 Market Cap and Company Size
Market cap is $24.6M, which is about About 0% the size of Samsung Electronics' market cap. The company has 10 people employees.
VYNE is a Nasdaq-listed micro-cap biotech with a very small market cap ($24.6M). At this scale, it is common for the stock to move by tens of percentage points on a single clinical readout or financing announcement. Unlike large-cap pharma, it should be understood as less of a "company" and closer to an "option bet on a single drug candidate."
📈 Vyne Therapeutics Outlook and Stock Price Trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe near-term focus for VYNE is the clinical progress of its oral BET inhibitor VYN202 in plaque psoriasis, as well as the direction of Repibresib (VYN201), for which the company is seeking a partner. After the vitiligo Phase 2b trial failed to meet its primary endpoint, that trial was halted, and the company shifted to a strategy of finding an external development partner.
The broader BET inhibitor market is highly competitive, with global large-cap pharma companies such as Novartis and Incyte running late-stage trials in myelofibrosis and hematologic cancers. For valuation, it is better to track clinical milestone schedules and cash burn rate (cash runway) together, rather than profitability metrics such as $-26.68 and -63.2%.
⚔️ Key Competitive Strengths and Risks
VYNE has the advantage of expertise focused on the innovative BET inhibitor target, but it carries the classic early-stage biotech profile of persistent clinical failure and financing risks.
💪 Key Competitive Strengths
⚠️ Key Risks
🔄 Competitors and Related Stocks (Beneficiaries)
The competitive landscape for BET inhibitors includes global large-cap pharma Novartis (NVS), Incyte (INCY) with a deep hematologic cancer pipeline, and TG Therapeutics (TGTX), which is developing BET-based hematologic cancer therapeutics. Related stocks include Bristol-Myers Squibb (BMY), which markets oral agents in the immune and inflammation space, as well as similarly sized clinical-stage biotechs in immune disease.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 INCY | Incyte Corp | $126.03 | +1.3% | $25.5B | 16.1 | 4.0 | 30.67% | - |
| NVS | Novartis AG ADR | $137.48 | -0.2% | $251.7B | 20.7 | 6.1 | 30.56% | 3.22% |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 TGTX | TG Therapeutics Inc | $54.65 | -2.0% | $8.4B | 19.9 | 13.8 | 100.28% | - |
| BMY | Bristol-Myers Squibb Co | $64.41 | -0.4% | $131.6B | 14.2 | 5.9 | 46.7% | 3.63% |
| ABBV | Abbvie Inc | $250.91 | +0.9% | $443.4B | 70.9 | - | 15221.82% | 2.74% |
✅ Investor Checkpoints
VYNE is an option-style stock where a single clinical data point can drive a large share price move. Be sure to check pipeline progress and cash runway before making an investment decision.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| VYN202 clinical progress | Check the schedule for clinical data readouts in plaque psoriasis and additional inflammatory indications. | Monitor IR and clinical disclosures |
| VYN201 partnership outcome | It is important to monitor the potential for co-development or licensing agreements with external pharma companies. | Check quarterly earnings calls |
| Cash runway | Use quarterly R&D and G&A spending and cash balance to estimate how many quarters of clinical activity can be supported. | Review quarterly financial statements |
| Competitor clinical pace | Approvals and clinical results from competing BET pipelines such as those of Novartis and Incyte will affect VYNE's positioning. | Follow industry news |
Any one of a clinical failure, an additional equity offering, or a delayed partnership could deliver a sharp share price shock. In addition, if a competitor reaches the market first, the commercial value of VYNE's candidates could shrink.
VYNE Therapeutics is a small biotech with a focus on the compelling BET inhibitor mechanism, with a clearly high-risk, high-reward profile. A disciplined approach is required — limiting its weight within the portfolio and reviewing clinical events and cash flow every quarter.
Check out Vyne Therapeutics' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free